P/E ratio for CRISPR Therapeutics (CRSP)
P/E ratio as of April 2024 (TTM): -10.2
According to CRISPR Therapeutics's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is -10.1585. At the end of 2022 the company had a P/E ratio of -4.86.
P/E ratio history for CRISPR Therapeutics from 2016 to 2023
PE ratio at the end of each year
| Year | P/E ratio | Change |
|---|---|---|
| 2022 | -4.86 | -131.98% |
| 2021 | 15.2 | -152.47% |
| 2020 | -28.9 | -152.75% |
| 2019 | 54.9 | -758.74% |
| 2018 | -8.33 | -39.34% |
| 2017 | -13.7 | -55.33% |
| 2016 | -30.7 |
P/E ratio for similar companies or competitors
| Company | P/E ratio | P/E ratio differencediff. | Country |
|---|---|---|---|
 ORIC Pharmaceuticals
ORIC | -3.70 | -63.54% | 🇺🇸 USA |
How to read a P/E ratio?
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.